Abstract
Three experiments evaluated the effects of estradiol valerate (EV) on ovarian follicular and CL dynamics, intervals to estrus and ovulation, and superovulatory response in cattle. Experiment 1 compared the efficacy of two norgestomet ear implants (Crestar and Syncro-Mate B; SMB) for 9 d (with PGF at implant removal), combined with either 5 mg estradiol-17β and 100 mg progesterone (EP) or 5 mg EV and 3 mg norgestomet (EN) im at the time of implant insertion on CL diameter and follicular wave dynamics. Ovaries were monitored by ultrasonography. There was no effect of norgestomet implant. Diameter of the CL decreased following EN treatment ( P < 0.01). Mean (± S.D.) day of follicular wave emergence (FWE) was earlier ( P < 0.0001) and less variable ( P < 0.0001) in EP- (3.6 ± 0.5 d) than in EN- (5.7 ± 1.5 d) treated heifers. Intervals from implant removal to estrus ( P < 0.001) and ovulation ( P < 0.01) were shorter in EN- (45.7 ± 11.7 and 74.3 ± 12.6 h, respectively) than in EP- (56.4 ± 14.1 and 83.3 ± 17.0 h, respectively) treated heifers. Experiment 2 compared the efficacy of EP versus EN in synchronizing FWE for superovulation in SMB-implanted cows. At random stages of the estrous cycle, Holstein cows ( n = 78) received two SMB implants (Day 0) and were randomly assigned to receive EN on Day 0 or EP on Day 1. Folltropin-V treatments were initiated on the evening of Day 5, with PGF in the morning and evening of Day 8, when SMB were removed. Cows were inseminated after the onset of estrus and embryos were recovered 7 d later. Non-lactating cows had more CL (16.7 ± 11.3 versus 8.3 ± 4.9) and total ova/embryos (14.7 ± 9.5 versus 7.9 ± 4.6) than lactating cows ( P < 0.05). EP-treated cows tended ( P = 0.09) to yield more transferable embryos (5.6 ± 5.2) than EN-treated cows (4.0 ± 3.7). Experiment 3 compared the effect of dose of EV on ovarian follicle and CL growth profiles and synchrony of estrus and ovulation in CIDR-treated beef cows ( n = 43). At random stages of the estrous cycle (Day 0), cows received a CIDR and no further treatment (Control), or an injection of 1, 2, or 5 mg im of EV. On Day 7, CIDR were removed and cows received PGF. Follicular wave emergence occurred within 7 d in 7/10 Control cows and 31/32 EV-treated cows ( P < 0.05). In responding cows, interval from treatment to FWE was longer ( P < 0.05) in those treated with 5 mg EV (4.8 ± 1.2 d) than in those treated with 1 mg (3.2 ± 0.9 d) or 2 mg (3.4 ± 0.8 d) EV, while Control cows were intermediate (3.8 ± 2.0 d). Diameter of the dominant follicle was smaller ( P < 0.05) at CIDR removal and tended ( P = 0.08) to be smaller just prior to ovulation in the 5 mg EV group (8.5 ± 2.2 and 13.2 ± 0.6 mm, respectively) than in the Control (11.8 ± 4.6 and 15.5 ± 2.9 mm, respectively) or 1 mg EV (11.7 ± 2.5 and 15.1 ± 2.2 mm, respectively) groups, with the 2 mg EV group (10.7 ± 1.5 and 14.3 ± 1.7 mm, respectively) intermediate. Diameter of the dominant follicle at CIDR removal was less variable ( P < 0.01) in the 2 and 5 mg EV groups than in the Control group, and intermediate in the 1 mg EV group. In summary, treatment with 5 mg EV resulted in a longer and more variable interval to follicular wave emergence than treatment with 5 mg estradiol-17β, which affected preovulatory dominant follicle size following progestin removal, and may have also affected superstimulatory response in Holstein cows. Additionally, 5 mg EV appeared to induce luteolysis in heifers, reducing the interval to ovulation following norgestomet removal. Conversely, intervals to, and synchrony of, follicular wave emergence, estrus and ovulation following treatment with 1 or 2 mg EV suggested that reduced doses of EV may be more useful for the synchronization of follicular wave emergence in progestogen-treated cattle.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.